Conatumumab

Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5) . Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. [1][2][3].

Product Specifications

CAS Number

[896731-82-1]

Product Name Alternative

AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/conatumumab.html

Purity

98.90

Solubility

10 mM in DMSO

Smiles

[Conatumumab]

Molecular Weight

(145.44 kDa)

References & Citations

[1]Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16 (23) :5883-91. |[2]Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9 (8) :618-31.